We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » IBM Unveils RFID Program to Battle Counterfeit Drugs

IBM Unveils RFID Program to Battle Counterfeit Drugs

August 15, 2006

IBM last week unveiled a radio-frequency identification (RFID) system for tracking and tracing pharmaceuticals. The system is designed to make it more difficult for counterfeit drugs to get to market, the company said.

The IBM RFID system for pharmaceutical track and trace uses blended RFID software and services to automatically capture and track the movement of drugs through the supply chain. RFID tags are embedded on products at the unit, case and pallet levels and authenticate the product from manufacturers to wholesalers to hospitals and pharmacies. Each tag contains a unique identifier that can be linked back to descriptive product information such as dosage and strength, lot number, manufacturer and expiration date.

Beyond Conterfeit Drugs

Some experts say that RFID’s usage will expand beyond the battle against counterfeit drugs. It’s just a matter of time before drug, device and biologics companies see the value in RFID and embrace the technology to improve product quality, speed recalls and work more efficiently and effectively with regulators, IBM’s RFID guru Paul Chang told PIR.

“The benefits of RFID are significant throughout the supply chain,” said Chang, Worldwide Development, EPCIS Solutions, IBM Software Group. He also testified July 13 as part of the Information Technology Industry Council before a Senate RFID forum to discuss its benefits in the healthcare industry.

The new IBM system helps manufacturers and distributors improve performance by reducing the cash tied up in inventory, targeting recalls and enabling faster response to market demand, IBM said in an Aug. 8 release.

The system is based on the IBM WebSphere software platform and an architecture that allows clients to reuse existing assets, thereby building new applications quickly and at a lower cost.

The FDA is also pushing RFID. In addition to calling on Congress to get involved in advocating it for anti-counterfeiting efforts, the FDA recently said it will “fully implement” regulations related to the Prescription Drug Marketing Act of 1987, requiring drug distributors to provide documentation of the chain of custody for drug products throughout the distribution system (PIR, June 21).

For more information on IBM’s RFID initiative, go to www.ibm.com/solutions/businesssolutions/sensors.

KEYWORDS Technology

    Upcoming Events

    • 28Sep

      The Cost of Counterfeiting: Why You Need a Plan to Secure Your Medical Device Supply Chain

    • 28Sep

      Calculating Sample Size to Satisfy FDA Expectations

    • 11Oct

      GMP Quality Management vSummit 2023: Where Quality Meets Risk

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    • 08Nov

      18th Annual FDA Inspections vSummit

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • Manufacturing Cost is Key Issue Facing Gene Therapy Products, Marks Says

    • Artificial Womb Technology Not Yet Ready for Human Trials Adcomm Says

    • Top Concern for CBER is Marketing of Unapproved Biologics, Says FDA Official

    • FDA Deems Medline Industries’ Saline Solution Vial Recall as Class 1

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing